Paper highlight: New driver of T cell leukemia growth

Sep 20, 2010

NKX3.1, a protein that suppresses the development of prostate tumors, promotes the growth of a different type of tumor in the blood, according to an article published online on September 20 in the Journal of Experimental Medicine.

Paul-Henri Romeo and colleagues find that TAL1, a abundantly expressed in approximately 40% of patients with T cell acute lymphoblastic leukemia (T-ALL), drives expression of NKX3.1. Eliminating NKX3.1 halted the growth of TAL1-expressing T-ALL cells in culture and after injection into mice.

It's not yet clear how NKX3.1 sustains the growth of T-ALL cells, but these findings show that this protein can either halt or hasten tumor development depending on the tissue environment.

Explore further: Cancer diagnosis and treatment need improvement

More information: Kusy, S., et al. 2010. J. Exp. Med. doi:10.1084/jem.20100745. http://www.jem.org/

add to favorites email to friend print save as pdf

Related Stories

Targeted Immune Cells Shrink Tumors in Mice

Feb 10, 2009

(PhysOrg.com) -- Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated ...

Strengthening the tumor-fighting ability of T cells

Mar 24, 2008

Researchers may have found a new way to promote immune cell attack on tumors. The new study, by a team of scientists in Milan, Italy, will be published online on March 24 in the Journal of Experimental Medicine.

Recommended for you

Bone loss drugs may help prevent endometrial cancer

5 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.